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Abstract Molecular mechanisms triggered by high dietary
beta-carotene (BC) intake in lung are largely unknown. We
performed microarray gene expression analysis on lung
tissue of BC supplemented beta-carotene 15,150-monooxy-
genase 1 knockout (Bcmo1-/-) mice, which are—like
humans—able to accumulate BC. Our main observation was
that the genes were regulated in an opposite direction in male
and female Bcmo1-/- mice by BC. The steroid biosynthetic
pathway was overrepresented in BC-supplemented male
Bcmo1-/- mice. Testosterone levels were higher after BC
supplementation only in Bcmo1-/- mice, which had, unlike
wild-type (Bcmo1?/?) mice, large variations. We hypothe-
size that BC possibly affects hormone synthesis or
metabolism. Since sex hormones influence lung cancer risk,
these data might contribute to an explanation for the previ-
ously found increased lung cancer risk after BC
supplementation (ATBC and CARET studies). Moreover,
effects of BC may depend on the presence of frequent human
BCMO1 polymorphisms, since these effects were not found
in wild-type mice.
Keywords Sex-hormones  Mouse whole genome
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Introduction
Beta-carotene (BC) is a lipid-soluble provitamin, and a major
dietary source of vitamin A. BC itself is thought to behave as
a health-promoting agent. This has been attributed to its
ability to efficiently scavenge radicals and thereby prevent
macromolecular damage [1]. Furthermore, epidemiological
studies focusing on dietary intakes of BC have indicated that
a high BC intake is associated with a reduced risk for the
development of cardiovascular diseases and several types of
cancer [2, 3]. Moreover, BC is a provitamin A, and therefore
its consumption prevents vitamin A deficiency, which is of
importance even in Western society. For example, pregnant
and lactating women are at risk for vitamin A deficiency in
the Western society due to the discouragement of the con-
sumption of food containing high amounts of vitamin A, in
combination with their increased requirements [4].
Although BC is mainly considered to be a health-
promoting agent, large-scale intervention trials failed to
confirm its beneficial properties. Two intervention trials
even showed an increased lung cancer risk and increased
mortality because of lung cancer in smokers after BC
supplementation (CARET study and ATBC study) [5, 6]. A
6-year follow-up of the CARET study showed differences
in lung cancer risk in response to BC supplementation
between male and female volunteers, while the ATBC
study was only executed in male volunteers. In the CARET
study, male subjects had an increased lung cancer risk upon
BC supplementation, but only for the duration of the BC
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intervention. On the other hand, BC-supplemented females
had an increased lung cancer risk that persisted even after
the intervention had stopped, and it took several years
before the lung cancer risk in females reached the levels
observed in the controls [7]. The BC-induced increase in
lung cancer risk is thought to occur only in smokers or
asbestos-exposed subjects since one large-scale interven-
tion trial with mainly non-smokers showed no effect of BC
on lung cancer [8, 9]. Although the effect of BC on lung
carcinogenesis has been studied extensively, the mecha-
nism by which BC increases lung cancer risk is still not
precisely known. The main reason for this is that research
on molecular pathways influenced by BC is hampered by
the lack of an appropriate animal model that also allows for
the use of state-of-the-art functional genomic tools, such as
commercially available microarrays. Mice and rats are
animal models for which these tools are commercially
available, but they differ greatly in BC metabolizing
activity compared to humans. The main cause for this is the
presence of a more active beta-carotene 15, 150-monoox-
ygenase 1 (Bcmo1) enzyme variant in rodents [10]. Bcmo1
is the key enzyme in BC metabolism, and in rodents,
Bcmo1 cleaves almost all absorbed BC. Since rodents
metabolize BC to a high degree, BC supplementation
results in an increase in BC metabolites rather than the
accumulation of BC, and rodents are therefore inadequate
animals to study the effects of BC in humans [10].
Not only inter-species differences in Bcmo1 activity
have been described, but also large inter-individual dif-
ferences in BCMO1 activity are present between humans.
Around 25–45% of the volunteers participating in BC
conversion studies have been classified as poor converters
[11–13]. These inter-individual differences in BC metab-
olism are at least partly related to polymorphisms in the
BCMO1 gene, which results in a reduced BCMO1 activity
[14, 15]. Of the reported polymorphisms, there are two
frequently occurring polymorphisms with variant allele
frequencies of 42 and 24%. As a result, individuals with
these polymorphisms have relatively low vitamin A and
high BC plasma concentrations compared to their wild-
type counterparts [14]. Since differences in activity of
BCMO1 result in different BC metabolite concentrations,
the activity of BCMO1 might therefore have an effect on
previously reported BC-induced effects.
The aim of our study was to investigate gene expression
changes induced by dietary BC to try to explain the previ-
ously found harmful effects of BC in the lung. For this
purpose we used a recently described mouse model, which
has no functional Bcmo1 enzyme and which therefore
displays increased BC plasma concentrations upon BC
supplementation [16]. We performed whole-genome
microarray gene expression analysis on lung tissue of both
female and male wild-type (Bcmo1?/?) and Bcmol
knockout (Bcmo1-/-) mice with or without 14 weeks of
150 mg/kg BC supplementation. We previously analyzed
the effects of BC in female Bcmo1-/- mice, and the major
effect observed was that BC supplementation counteracted
inflammation associated gene expression effects, which
were most likely caused by an increased vitamin A demand
in Bcmo1-/- mice [17]. This effect was not observed in
male Bcmo1-/- mice, where two genes, Frizzled 6 (Fzd6)
and Collagen triple helix receptor containing 1 (Cthrc1)
were strongly downregulated by BC supplementation,
which was not observed in female mice [18]. Thus, the
major BC-affected processes seemed different between
both genders. However, both females and males displayed
increased cancer risk after BC supplementation during the
intervention of the CARET study. Therefore, we aimed to
specifically focus on those genes that are commonly regu-
lated by BC supplementation in both genders, i.e., in male
as well as female Bcmo1-/- mice.
Materials and methods
Animals and treatment
The experimental setup has been described previously
(females, [17] and males [18]). Twelve female (fe) and
12 male (ma) B6129SF1 (Bcmo1?/?) and 12 female and
12 male B6;129S-Bcmo1tm1dnp (Bcmo1-/-) mice [16] were
used for the dietary intervention, which was conducted in
accordance with the German animal protection laws by the
guidelines of the local veterinary authorities. During the
breeding and weaning periods of the mice, mothers were
maintained on KLIBA 3430 chow containing 14,000 IU
vitamin A/kg diet (Provima Kliba AG, Kaiseraugst, Swit-
zerland). Five-week-old female and male Bcmo1?/? and
Bcmo1-/- mice were caged in groups containing two to
four siblings per group and were maintained under envi-
ronmentally controlled conditions (temperature 24C,
12 h/12 h light/dark cycle). Mice had ad libitum access to
feed and water. Basic feed consisted of the pelletized diet
D12450B (Research Diets Inc, USA) with a fat content of
10%. The diet was modified to contain 1,500 IU vitamin
A/kg of diet, which is a vitamin A-sufficient diet, and the
control diet (control) was supplemented with water-soluble
vehicle beadlets (DSM Nutritional Products Ltd., Basel,
Switzerland) containing DL-alpha-tocopherol and ascorbyl
palmitate as stabilizers, as well as carriers such as gelatin,
corn oil sucrose and starch. The BC diet (BC) was sup-
plemented with identical water-soluble beadlets containing
BC (DSM Nutritional Products Ltd., Basel, Switzerland) to
generate 150 mg BC/kg diet. Beadlets were added by the
manufacturer before low temperature pelletting. Feed
pellets were color marked and stored at 4C in the dark.
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After 14 weeks of dietary intervention, six female and
six male Bcmo1?/? mice on the control diet (Bcmo1?/?
Co), six female and six male Bcmo1?/? mice on the BC
diet (Bcmo1?/? BC), three female and six male Bcmo1-/-
mice on the control diet (Bcmo1-/- Co), and three female
and six male Bcmo1-/- mice on the BC diet (Bcmo1-/-
BC) were randomly killed on three subsequent mornings.
Due to an insufficient number of female Bcmo1-/- mice in
the original breeding pool, six additional female Bcmo1-/-
mice were used that were born 2 weeks later from an
identical experiment, three were fed the control diet and
three the BC diet, to generate n = 6 for each group. These
mice were killed 2 weeks after the first group of mice.
Blood was collected from the vena cava after isoflurane
and ketamin anesthesia. Blood was coagulated for at least
20 min at room temperature, cooled to 4C and centri-
fuged. Lung tissue was removed, rinsed in phosphate-
buffered saline (PBS) and snap frozen in liquid nitrogen.
The lung tissues were stored at -80C.
RNA isolation
Left lung lobes were homogenized in liquid nitrogen using a
cooled mortar and pestle. Total RNA was isolated using
TRIzol reagent (Invitrogen, Breda, The Netherlands)
followed by purification using RNeasy columns (Qiagen,
Venlo, The Netherlands) using the instructions of the
manufacturer. RNA concentration and purity were mea-
sured using the Nanodrop system (IsoGen Life Science,
Maarsen, The Netherlands). Approximately 30 lg of total
RNA was isolated with A260/A280 ratios above 2 and
A260/A230 ratios above 1.9 for all samples, indicating good
RNA purity. RNA degradation was checked on the Experion
(Bio-Rad, Veenendaal, The Netherlands) using Experion
StdSense chips (Bio-Rad). Two samples did not meet RNA
quality (female Bcmo1?/? mice, one on BC diet and one on
control diet) and were omitted from the experiment.
Microarray hybridization procedure
The 4 9 44 k Agilent whole mouse genome microarrays
(G4122F, Agilent Technologies, Inc. Santa Clara, CA) were
used. Preparation of the sample and the microarray hybrid-
ization were carried out according to the manufacturer’s
protocol with a few exceptions as described previously [19,
20]. In brief, cDNA was synthesized from 1 lg lung RNA
using the Agilent Low RNA Input Fluorescent Linear
Amplification Kit for each animal without addition of
spikes. Thereafter, samples were split in two equal amounts
to synthesize Cyanine 3-CTP (Cy3) and Cyanine 5-CTP
(Cy5) labeled cRNA using half the amounts per dye as
indicated by the manufacturer (Agilent Technologies).
Labeled cRNA was purified using RNeasy columns
(Qiagen). Yield, A260/A280 ratio, and Cy3 or Cy5 incorpo-
ration were examined for every sample using the nanodrop.
All samples met the criteria of a cRNA yield higher than
825 ng and a specific activity of at least 8.0 pmol Cy3 or
Cy5. Then 1,200 ng of every Cy3-labeled cRNA sample was
pooled and used as a common reference pool. Individual
825 ng Cy5-labeled cRNA and 825 ng pooled Cy3-labeled
cRNA were fragmented in 19 fragmentation and 19
blocking agent (Agilent Technologies) at 60C for 30 min
and thereafter mixed with GEx Hybridization Buffer
HI-RPM (Agilent Technologies) and hybridized in a 1:1
ratio at 65C for 17 h in an Agilent Microarray hybridization
Chamber rotating at 4 rpm. After hybridization, slides were
washed according to the wash protocol with Stabilization
and Drying solution (Agilent Technologies). Arrays were
scanned with an Agilent scanner with 10 and 100% laser
power intensities (Agilent Technologies).
Data analyses of microarray results
Signal intensities for each spot were quantified using
Feature Extraction 9.1 (Agilent Technologies). Median
density values and background values of each spot were
extracted for both the experimental samples (Cy5) and the
reference samples (Cy3). Quality control for every micro-
array was performed visually, by using quality control
graphs from Feature Extraction, M-A plots and boxplots
that were made using limmaGUI in R (Bioconductor) [21].
Data were imported into GeneMaths XT 2.0 (Applied
Maths, Sint-Martens-Latem, Belgium).
The median Cy5 signal intensity per spot per array was
used for the individual gene expression, while the median
Cy3 signal intensity was used for normalization. Since
values close to the background may give aberrant fold
changes between groups, spots with an average Cy5 or Cy3
median density value below two times the average of the
background density were discarded. Spots with an average
of the median Cy5 and Cy3 densities twice above the
average of the background density were selected and log
transformed. Thereafter, the log transformed Cy5 median
density value was normalized against the fold change in the
log-transformed Cy3 median density value compared to the
average log-transformed Cy3 median density value for each
spot as described before [22]. Pathway analysis was per-
formed using Gene-Ontology (GO) overrepresentation
analysis (ErmineJ) [23], and classification of genes was
based on OMIM (www.ncbi.nlm.nih.gov), genecards (www.
genecards.org) and literature mining.
Analysis of mRNA expression by real-time Q-PCR
Differential gene expression of lecithin-retinol acyltrans-
ferase (phosphatidylcholine-retinol-O-acyltransferase)
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(Lrat), glutamate receptor, ionotropic, AMPA1 (alpha 1)
(Gria1) and endothelin 1 (Edn1) was analyzed using
quantitative PCR (Q-PCR) to validate microarray results.
Then 1 lg RNA isolated from lung of individual animals
was converted into cDNA using the iScript cDNA Synthesis
Kit (Bio-Rad). One sample was taken along without reverse
transcriptase to examine the presence of DNA (without RT
reaction). An equal amount of cDNA of all individual
samples was pooled and diluted (109, 31.69 1009, 3169
1,0009, 3,1609, 10,0009) for the generation of a calibra-
tion curve to test the efficiency of the Q-PCR reaction. Each
PCR reaction (25 ll) contained 19 iQ SYBR green
supermix (Bio-Rad), 10 lM sense primer, 10 lM antisense
primer and 2 ll 100 times diluted cDNA. Primers for Lrat
were sense 50-GCTCTCGGATCAGTCCACAGGC-30 and
antisense 50-TCCCAAGACAGCCGAAGCAAGA-30, for
Gria1 sense 50-TGGTGGTGGTGGACTGTGAATC-30 and
antisense 50-CAGGTTGGCGAGGATGTAGTGG-30 and
for Edn1 sense 50-AGACCAGGCAGTTAGATGTCAGTG
and antisense 50-TCGTAGTTTCCTTCCTTCCACCAG.
For the amplification of the reference genes we used syn-
taxin 5a (Stx5a) with sense 50-TTAAAGAACAGGAGG
AAACGATTCAGAG-30 and antisense 50-CAGGCAAGG
AAGACCACAAAGATG-30, and ring finger protein 130
(Rnf130) with sense 50-ACAGGAACCAGCGTCGTCT
TG-30 and antisense 50-ACCCGAACAACATCATTCTGC
TTATAG-30, which showed equal gene expression levels
for all individual animals on the microarray. These intron-
spanning primers were designed using Beacon designer
7.00 (Premier Biosoft International, Palo Alto, CA) or using
primer-BLAST (http://www.ncbi.nlm.nih.gov/). Amplifi-
cation was performed in duplicate using the MyIQ single-
color real-time PCR detection system (Bio-Rad) using
the following temperature cycles: 19 3 min at 95C, 409
2-step amplification (15 s 95C, 45 s 60C), 19 1 min
95C, and 19 1 min 65C followed by melting curve
analysis (609 10 s 65C with an increase of 0.5C/10 s.
A negative control without cDNA template and the minus
reverse transcriptase sample were taken along with every
assay. Using the standard curves for every gene, the relative
level of expression of all genes was calculated. Normalized
Gene Expression (DDCt) analysis was calculated using the
IQ5 software version 2.0 (Bio-Rad).
Testosterone measurement
Testosterone concentrations were measured using radio
immunoassays (DSL 4100, Diagnostic Systems Laborato-
ries, Beckman Coulter, Assendelft, The Netherlands) and
were performed according to the manufacturer’s protocol
using quarters of all volumes as has been described
previously [24]. Gamma-radiation was measured on a
Wallac 1470 Wizard Gamma Counter (Perkin-Elmer). The
recovery of testosterone spikes and linearity of the dilution
were tested before use.
Statistical analysis
General effects of diet, gender and genotype on concen-
trations of BC, retinol and retinyl esters in lung and serum
were analyzed using 2 9 2 9 2 factorial univariate
ANOVA (SPSS version 15.0) and considered statistically
significant when p \ 0.05. Effects of BC compared to
control diet were tested using a Student’s t-test and con-
sidered statistically significant at p \ 0.05). Fold changes
for both microarray gene expression and Q-PCR gene
expression were calculated using mean log signal intensi-
ties. P-values for differential expressions were calculated
between two groups using two-tailed Student’s t-test sta-
tistics on log intensity values. Changes were considered
statistically different at p \ 0.05. Regression analysis of
gene expression in males versus females was performed in
GraphPad Prism software (version 5.0; GraphPad Software,
Inc, San Diego, CA) using nonlinear regression analysis.
Results
BC supplementation and knockout of Bcmo1 results
in changes in BC and BC metabolites
BC concentrations in lung and serum were increased after
14 weeks of BC treatment compared to control diet-fed
mice, and as expected, to a higher level in Bcmo1-/- mice
as in Bcmo1?/? mice (as has been described separately for
female [17] and male [18] mice). There were no significant
differences in retinol serum concentrations between the
different groups. In lung tissue, retinol and retinyl ester
concentrations were increased upon BC supplementation
compared to the control diet fed mice, but there was no
interaction between BC and the Bcmo1 genotype con-
cerning the concentration of these metabolites (Fig. 1).
Gene expression of all groups was analyzed, and of the
43,379 spots (number of spots minus control spots) on the
whole genome microarrays, 31,128 spots had an average
signal twice above background and were regarded as
positive spots and included in the analysis. There were two
genes involved in downstream BC metabolism that were
significantly regulated by BC in Bcmo1?/? mice (Table 1).
The biggest fold change was found for lecithin-retinol
acyltransferase (phosphatidylcholine-retinol-O-acyltrans-
ferase (Lrat; 1.6 fold increase after BC supplementation).
Five genes involved in downstream BC metabolism were
regulated because of the knock-out of Bcmo1. Most strik-
ing was the high fold change up regulation of Lrat (1.7–2.1
fold increase in Bcmo1-/- mice) and the high fold change
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down regulation of alcohol dehydrogenase 7 (class IV),
mu or sigma polypeptide (Adh7; 1.6–2.7 fold decrease in
Bcmo1-/- mice).
Gene expression is changed in the opposite direction
by BC in male and female Bcmo1-/- mice
BC supplementation resulted in a considerably higher
number of significantly regulated spots in the Bcmo1-/-
mice than in the Bcmo1?/? mice (Fig. 2a, b). Only 20
regulated genes overlapped in male and female Bcmo1?/?
mice and 89 genes in Bcmo1-/- mice. These two groups of
regulated genes commonly affected in both genders showed
no overlap between Bcmo1-/- and Bcmo1?/? mice. To
further determine whether these genes were similarly reg-
ulated by BC in both genders, fold changes of gender-
independent BC-regulated genes were plotted for female
mice against the fold changes in male mice. The 20 BC-
regulated genes in male and female Bcmo1?/? mice were
distributed in all four quadrants of the plot (Fig. 2c).
Regression analysis resulted in a significant correlation
[R = 0.66; slope = 0.787; 95% CI slope = (0.2988–
1.276)]. This correlation was however based on only two
data points (-1.93; -1.87) and (1.34; 1.56). Without these
two points, there was no significant correlation [R = 0.14;
slope = -0.193; 95% CI slope = (-0.8832; 0.4960)]. To
our surprise, genes regulated by BC in female Bcmo1-/-
were regulated in opposite directions compared to BC-
regulated genes in male Bcmo1-/- mice (upwards regulated
genes in males were down in females and vice versa), with
only 4 out of the 89 probes being regulated in the same
direction (in italics in Table 3). We found [95% of the
probes being regulated in the opposite direction by BC
between males and females, suggesting that this is a real
effect of BC. Randomly affected gene expression would
theoretically result in 50% of the probes being regulated in a
similar direction and 50% in opposite directions. Regres-
sion analysis resulted in a significant negative regression
[R = 0.76; slope = -0.436; 95% CI slope = (-0.5144;
-0.3582)]. Genes regulated by BC in both male and female
Bcmo1?/? mice (Table 2) or Bcmo1-/- mice (Table 3)
were categorized into biological processes, with endothelial
functioning, immune response and nervous response being
most prominently regulated by BC in Bcmo1-/- mice
(Fig. 3).
We used Q-PCR to validate the microarray experiment.
For validation of the effects in Bcmo1?/? mice, lecitin retinol
acyltransferase (phosphatidylcholine-retinol O-acyltrans-
ferase) (Lrat), an enzyme involved in downstream BC
metabolism, was selected. For validation of effects induced
Fig. 1 Beta-carotene (BC) (a, c), retinol (b, d) concentrations in
serum and lung tissue, respectively, and retinyl ester concentrations in
lung tissue (e) of female and male Bcmo1?/? mice and Bcmo1-/-
mice fed a control diet (white bars) or a BC diet (black bars). Data are
expressed as mean ± SEM; significance was tested for diet (BC),
gender (S) and genotype (G) using ANOVA and considered
significant at p \ 0.05. Significant effects for the different factors
or any interaction between those factors are displayed on top of each
figure. Student’s t-test was used between BC and control groups when
there was a significant diet effect by ANOVA and considered
significant when p \ 0.05. Using Student’s t-test statistics: *p \ 0.05,
**p \ 0.01 and ***p \ 0.001
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by BC supplementation in Bcmo1-/- mice, the genes glu-
tamate receptor, ionotropic, AMPA1 (alpha 1) (Gria1) and
endothelin 1 (Edn1) were chosen because of their relatively
high expression level and relatively high fold changes. All
three selected genes showed an identical expression using
the microarray technique and Q-PCR (Fig. 4).
BC supplementation results in the overrepresentation
of the steroid biosynthetic process
in male Bcmo1-/- mice
Gene-ontology processes affected by BC supplementation
in male and female Bcmo1-/- mice were examined to
further explain the opposite direction of gene expression
induced by BC. This overrepresentation analysis was per-
formed using ErmineJ overrepresentation analysis [23] on
all genes and their corresponding p-value. We found a
significant overrepresentation of the steroid biosynthetic
process (GO:0006694) in male Bcmo1-/- mice by BC
supplementation (p = 4.6 9 10-6), but not in female
Bcmo1-/- mice (p = 0.17). Genes regulated by BC
resulting in the overrepresentation of the steroid biosyn-
thetic process in male Bcmo1-/- mice are listed in Table 4
(genes presented until p = 0.1).
Effect of BC on serum testosterone levels
We determined serum concentrations of the sex hormone
testosterone. Since only limited amounts of serum were
available, other sex hormones requiring bigger serum
amounts could not be determined. As expected, testoster-
one levels were significantly higher in Bcmo1?/? males
than in Bcmo1?/? females (Fig. 5a). In Bcmo1-/- mice,
however, testosterone levels showed a high inter-individual
variability (Fig. 5b). Due to this large variation, there was
no statistically significant difference in testosterone levels
between male and female Bcmo1-/- mice. However, BC
increased testosterone levels in both Bcmo1-/- female and
male mice with a fold change of 4.7 and 4.0, respectively
(Fig. 5c), although, because of the high variation, differ-
ences did not reach statistical significance (ANOVA; effect
of diet p = 0.12 and interaction effect of diet with Bcmo1
genotype p = 0.14).
Discussion
We showed for the first time that BC supplementation to
Bcmo1-/- mice resulted in the regulation of gene expres-
sion in opposite directions in male and female mice. We
hypothesize that BC alters systemic hormone production,
which was supported by the overrepresentation of theT
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steroid biosynthetic process (GO:0006694) in male
Bcmo1-/- mice upon consumption of a BC diet
(p = 4.6 9 10-6). Moreover, testosterone concentrations
were increased, but highly variable after BC supplemen-
tation in Bcmo1-/- mice. The presence of an active Bcmo1
enzyme was of importance in the observed opposite
direction of gene expression changes induced by BC sup-
plementation in male and female mice, since these effects
were not observed in Bcmo1?/? mice.
BC supplementation to Bcmo1-/- mice resulted in an
opposite direction of gene regulation in males and females.
A hypothesis to explain this is that BC supplementation
induces alterations in sex hormone synthesis or metabolism
in male and female mice. Interestingly, the biosynthetic
pathway for BC production in plants partly overlaps with
the steroid biosynthetic pathway in animals [25]. To sup-
port this hypothesis, we measured testosterone levels in
serum, which were highly variable in BC-supplemented
Bcmo1-/- mice, but not in the other groups. Another
important sex hormone that might have been changed after
BC supplementation to Bcmo1-/- is 17b-estradiol, but the
amount of serum left did not allow us to measure this.
Although we were not able to technically prove a change in
sex hormones, a change in sex hormones would result in a
gender-specific change since the lung contains all neces-
sary elements for sex hormone action, such as enzymes
involved in androgen and estrogen metabolism as well as
estrogen and androgen receptors [26–28]. In line with this,
the GO process for steroid biosynthesis was significantly
regulated in male lung tissue, as can be seen in Table 4.
Several enzymes involved in steroid conversion were
shown to be significantly regulated in male Bcmo1-/-
mice. For example, testosterone can be converted in the
lung into estrone and 17b-estradiol. 17b-Estradiol can bind
to the estrogen receptor to induce estrogen-related
responses [29]. Interestingly, the gene expression of
17-beta-hydroxysteroid dehydrogenase 12 (Hsd17b12),
which converts estrone into estradiol, was significantly
upregulated [30], and steroid 5 alpha-reductase 1 (Srd5a1),
an important enzyme in the inactivation of testosterone
[27], was downregulated (p = 0.055) in lungs of male
Bcmo1-/- mice upon BC supplementation. Moreover,
17-beta-hydroxysteroid dehydrogenase 7 (Hsd17b7), which
oxidizes or reduces estradiol, and thus decreases the
estrogenic potency, was significantly downregulated by BC
in female Bcmo1-/- mice. These data indicate that BC
might have had an effect on sex hormone synthesis and had
an effect on hormone conversion in male Bcmo1-/- mice.
Further research is needed to elucidate the exact mecha-
nism underlying the observed opposite change in gene
regulation induced by BC supplementation in male and
female Bcmo1-/- mice.
Although the number of studies that have assessed
effects of BC on hormone production is limited, these
studies actually support a relation between BC and steroid
hormone alterations. BC supplementation to female dogs
resulted in increased plasma progesterone concentrations
[31], and cats supplemented with BC had increased estra-
diol concentrations [32]. In addition, it has been reported
that downstream BC metabolites, such as vitamin A and
the bioactive metabolite retinoic acid, also have an effect
on steroidogenesis and that these effects are, at least in part,
due to an increased expression of enzymes involved in
steroidogenesis [33, 34]. It is not known whether previ-
ously described effects of downstream BC metabolites on
steroidogenesis are regulated by binding of retinoic acid to
Fig. 2 Venn diagrams
representing the number of
genes significantly (p \ 0.05)
regulated by BC in female and
male mice and the number of
genes regulated by BC in both
females as well as males
(overlap) in Bcmo1?/? (a) and
Bcmo1-/- (b) mice. The scatter
plots represent the gene
expression fold changes of the
genes regulated by BC
independent of gender in
females (x-axis) and males
(y-axis) in Bcmo1?/? (c) and
in Bcmo1-/- (d) mice
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the transcription factors retinoic acid receptor (RAR) or
rexinoid X receptor (RXR).
Our results suggest that the BC-induced opposite
direction of gene expression in the different genders of
Bcmo1-/- mice was due to an increase in BC concentration
and not due to a change in BC metabolites such as retinoic
acid, since this opposite direction of gene expression reg-
ulation was only observed in Bcmo1-/- mice. Compared
to Bcmo1-/- mice, male and female Bcmo1?/? mice had
higher concentrations of the BC metabolites; retinol and
retinyl esters accumulated in lung tissue after BC supple-
mentation. Furthermore, although still not fully understood,
it is generally believed that retinoic acid concentrations are
well regulated [35]. Nevertheless, it may be that the con-
centration of the bioactive metabolite retinoic acid, able to
bind to RAR and RXR, is altered only in Bcmo1-/- mice
and not in Bcmo1?/? mice. We previously reported that the
Bcmo1-/- mice were more prone to a phenotypic vitamin
A deficiency than Bcmo1?/? mice due to alterations in the
expression of downstream BC-metabolizing enzymes
important in the production of retinoic acid [17]. Supple-
mental BC was able to restore this phenotype. We similarly
show in this study that downstream BC metabolism was
altered in Bcmo1-/- mice. Most striking was the upregu-
lation of Lrat combined with the downregulation of Adh7
in Bcmo1-/- mice. Lrat is involved in the storage of retinol
by the formation of retinyl esters [36], while Adh7 is
involved in the conversion of retinol into retinal, which is
the precursor for retinoic acid [37]. This therefore impli-
cates a more vitamin A-storing phenotype of Bcmo1-/-
mice compared to Bcmo1?/? mice. Moreover, more
enzymes involved in downstream BC metabolism were
altered, and altogether these data indicate that also a
change in retinoic acid, possibly because of a less tight
regulation of retinoic acid stores in Bcmo1-/- mice com-
pared to Bcmo1?/? mice, might explain the observed
alterations in hormone production.
Another question is whether the processes that were
regulated by BC supplementation in lung tissue of
Bcmo1-/- mice are known to respond to hormonal
Fig. 3 Classification of genes that are regulated by BC (p \ 0.05) in
male as well as in female Bcmo1-/- mice into different biological
process categories
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changes. The BC-regulated genes in lungs of Bcmo1-/-
mice in this study were mainly categorized into three
biological categories: endothelial functioning, immune
response and nervous response. A literature search
revealed that these three categories are all affected by one
gaseous mediator: nitric oxide (NO). NO is a radical and
can be produced endogenously by the iron-containing
enzyme nitric oxide synthase (Nos). Three distinct NOS
isoforms have been characterized, neuronal NOS (nNOS or
NOSI), inducible NOS (iNOS or NOSII) and endothelial
NOS (eNOS or NOSIII), and all three NOS isoforms have
been detected in the airway epithelium [38, 39]. The
functions of NO in the airway include neurotransmission,
vascular tone homeostasis and regulation of immune
functioning [40]. In our microarray, only NOSIII had an
expression twice above background, and there were no
Fig. 4 The fold change gene expression of Lrat in Bcmo1?/? mice
(a), Gria in Bcmo1-/- mice (b) and Edn1 in Bcmo1-/- mice (c) in
BC supplementated mice relative to the control diet fed mice in the
microarray, validated by Q-PCR using the reference genes Stx5a and
Rnf130. Data represent the average gene expression ± SEM com-
pared to control diet fed mice. Using Student’s t-test statistics on log
transformed data: *p \ 0.05 and **p \ 0.01
Table 4 Genes regulated by BC in male Bcmo1-/- mice resulting in a significant overrepresentation of the steroid biosynthetic process
(GO: 0006694)a
Probe namer Source symbol Gene name BC-induced fold change gene expression
Bcmo1-/- mice
Female Male
A_52_P137371 Hmgcr 3-Hydroxy-3-methylglutaryl-Coenzyme A reductase -1.08 (0.29) 1.14 (0.01)
A_51_P413238 Pbx1 Pre B-cell leukemia transcription factor 1 1.02 (0.68) -1.11 (0.02)
A_51_P309733 Cyp11a1 Cytochrome P450, family 11, subfamily a, polypeptide 1 1.06 (0.50) 1.20 (0.02)
A_51_P169527 Mvk Mevalonate kinase -1.05 (0.48) 1.11 (0.03)
A_52_P165654 Star Steroidogenic acute regulatory protein 1.09 (0.41) 1.12 (0.03)
A_52_P384574 Stard4 StAR-related lipid transfer (START) domain containing 4 1.07 (0.54) -1.27 (0.04)
A_52_P223224 Dhrs8 Dehydrogenase/reductase (SDR family) member 8 -1.02 (0.63) 1.11 (0.04)
A_51_P515446 Cyp39a1 Cytochrome P450, family 39, subfamily a, polypeptide 1 1.01 (0.83) 1.08 (0.05)
A_52_P164570 Hsd17b12 Hydroxysteroid (17-beta) dehydrogenase 12 1.00 (0.95) -1.15 (0.05)
A_52_P85765 Stard6 StAR-related lipid transfer (START) domain containing 6 -1.05 (0.51) 1.11 (0.05)
A_51_P420415 Srd5a1 Steroid 5 alpha-reductase 1 -1.00 (0.98) 1.12 (0.06)
A_51_P485791 Cyp51 Cytochrome P450, family 51 -1.10 (0.14) 1.14 (0.06)
A_52_P566605 Hsd17b7 Hydroxysteroid (17-beta) dehydrogenase 7 -1.18 (0.03) 1.09 (0.07)
A_52_P136138 Fdft1 Farnesyl diphosphate farnesyl transferase 1 -1.08 (0.33) 1.18 (0.07)
A_52_P388072 Hmgcs1 3-Hydroxy-3-methylglutaryl-Coenzyme A synthase 1 -1.10 (0.22) 1.16 (0.08)
A_52_P636752 Cyp51 Cytochrome P450, family 51 -1.13 (0.19) 1.15 (0.08)
A_51_P379798 Fdps Farnesyl diphosphate synthetase -1.04 (0.65) 1.14 (0.08)
A_51_P485946 Fdft1 Farnesyl diphosphate farnesyl transferase 1 -1.15 (0.20) 1.07 (0.10)
a Genes presented: BC versus control in male Bcmo1-/- mice p \ 0.1; between brackets the actual p-value
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significant differences in gene expression after BC sup-
plementation. It is known that estrogen and testosterone
can have opposite effects on NO production resulting from
NOS activity [41]. An effect of BC on sex hormone pro-
duction may therefore result in a change in expression of
genes that are mediated by NO in opposite directions in
male and female lungs. Thus, when BC-induced changes in
hormone production, this possibly results in differences in
NO production, which might explain that particularly genes
involved in immune response, nervous response and
endothelial functioning were changed after BC supple-
mentation to male and female Bcmo1-/- mice.
A last point that we would like to address is whether
changes in hormone production or metabolism induced by
BC could possibly explain an increase in lung cancer risk
as observed in the CARET and ATBC studies. If this is
the case, than hormones are a determining factor in lung
carcinogenesis, resulting in gender-related differences in
lung cancer risk. Indeed, females are thought to have a
higher risk for the development of smoke-induced lung
cancer than males [42, 43], and lung cancer is more fre-
quent in never-smoking females than in never-smoking
males [44]. It has been hypothesized that especially
estrogens might be an important contributor to the dif-
ferences in lung cancer risk between the different genders.
For example, estrogen replacement therapy increases
lung cancer risk, and early menopause, which results in
decreased estrogen levels, which is associated with a
reduced risk for lung cancer in women [45]. Therefore,
BC-induced changes in hormone production could be an
explanation for part of the increases in lung cancer risk in
the CARET and ATBC studies.
In summary, we used Bcmo1-/- mice to investigate BC-
induced alterations in gene expression in lung. We unex-
pectedly found that BC supplementation resulted in an
opposite direction of gene expression in male and female
Bcmo1-/- mice. We hypothesize that BC supplementation
to Bcmo1-/- mice resulted in changes in hormone pro-
duction or metabolism, which would explain our opposite
effects on lung gene expression. To fully understand and
explain these effects, further research is needed specifically
focusing on reproductive organs as potential target organs
for BC and on quantitative measurements of sex hormones
in response to BC supplementation in males and in females.
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